Evidence for a central mechanism of action of S-(+)-ketoprofen

European Journal of Pharmacology

Volumn 483, Issue 2-3, 2004, Pages 241-248

  Díaz Reval, María Irene ^a   Ventura Martínez, Rosa ^b   Déciga Campos, Myrna ^b   Terrón, José A ^b   Cabré, Francesc ^c,d   López Muñoz, Francisco Javier ^b  

^a UNIVERSIDAD DE COLIMA   (Mexico)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

^c Menarini Research   (Spain)

^d Preclinical Pharmacology   (Spain)

Author keywords

5 HT receptor antagonist; Antinociception; Methiothepin; Tropisetron

Indexed keywords

ARGININE; KETOPROFEN; METITEPINE; N(G) NITROARGININE METHYL ESTER; NALOXONE; SEROTONIN 1 RECEPTOR; SEROTONIN 2 RECEPTOR; SEROTONIN 3 RECEPTOR; SEROTONIN 5 RECEPTOR; TROPISETRON;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; EXPERIMENTAL MODEL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONIN RELEASE; SEROTONINERGIC NERVE CELL;

EID: 0346687642     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2003.10.036     Document Type: Article

References (46)

1. Bagán J.V., López A.S., Valencia E., Santamaría J., Eguidazu I., Horas M., Foros M., Zapata A., Artigas R., Mauleón D. Clinical comparison of dexketoprofen tromethiothepinamol and dipyrone in postoperative dental pain. J. Clin. Pharmacol. 38:1998;55S-64S.
2. Barbanoj M., Gich I., Artigas R., Tost D., Moros C., Antonijoan R., García L., Mauleón D. Pharmacokinetics of dexketoprofen tromethamol in healthy volunteers after single and repeated oral doses. J. Clin. Pharmacol. 38:1998;33S-40S.
3. Bardin L., Lavarenne J., Eschalier A. Serotonin receptor subtypes involved in the spinal antinociceptive effect of 5-HT in rats. Pain. 86:2000;11-18.
4. Beltran J., Martin-Mola E., Figueroa M., Granados J., Sanmarti R., Artigas R., Torres F., Forns M., Mauleon D. Comparison of dexketoprofen trometamol and ketoprofen in the treatment of osteoarthritis of the knee. J. Clin. Pharmacol. 38:1998;74S-80S.
5. Björkman R. Central antinociceptive effects of non-steroidal anti-inflammatory drugs and paracetamol. Acta Anaesthesiol. Scand. 39(103):1995;1-44.
6. Björkman R., Hedner J., Hedner T., Henning M. Central, naloxone-reversible antinociception by diclofenac in the rat. Naunyn-Schmiedeberg's Arch. Pharmacol. 342:1990;171-176.
7. Cabré F., Fernandez M.F., Calvo L., Ferrer X., García M.L., Mauleón D. Analgesic, antiinflammatory and antipyretic effects of S(+)-ketoprofen in vivo. J. Clin. Pharmacol. 38:1998;3S-10S.
8. Carabaza A., Cabré F., Rotllán E., Gómez M., Gutiérrez M., García L., Mauleón D. Stereoselective inhibition of inducible cyclooxygenase by chiral nonsteroidal antiinflammatory drugs. J. Clin. Pharmacol. 36:1996;505-512.
9. Caroit M., Forette B., Hubault A., Pasquier P. Double-blind study of ketoprofen against a placebo in osteoarthritis of the hip. Scand. J. Rheumatol., Suppl. 1976:1976;123-127.
10. Cesselin F., Laporte A.M., Miquel M.C., Bourgoin S., Hamon M. Serotonergic mechanisms of pain control. Gebhart G.F., Hammond D.L., Jensen T.S. Progress in Pain Research and Management, Vol. 2, Proc. of the VIIth World Congress on Pain, Seattle. 1994;669-695 IASP Press, Seattle, WA, USA.
11. Covino B.G., Dubner R., Gybels J., Kosterlitz H.W., Liebeskind J.C., Sternbach R.A., Vyklicky L., Yamamura H., Zimmermann M. Ethical standards for investigations of experimental pain in animals. Pain. 9:1980;141-143.
12. Dickenson A.H., Chapman V., Green G.M. The pharmacology of excitatory and inhibitory amino acid-mediated events in the transmission and modulation of pain in the spinal cord. Gen. Pharmacol. 28:1997;633-638.
13. Ezcurdia M., Cortejoso F.J., Lanzón R., Ugalde F.J., Herruzco A., Artigas R., Fernández F., Torres F., Mauleón D. Comparison of the efficacy and tolerability of dexketoprofen and ketoprofen in the treatment of primary dysmenorrhea. J. Clin. Pharmacol. 38:1998;65S-73S.
14. Famaey J.P., Colinet E. A double-blind trial of ketoprofen in the treatment of osteoarthritis of the hip. Rheumatol. Rehabil. 15:1976;45-49.
15. Garthwaite J. Glutamate, nitric oxide and cell-cell signalling in the nervous system. Trends Neurosci. 14:1991;60-67.
16. Garthwaite J., Charles S.L., Chess-Williams R. Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intracellular messengers in the brain. Nature. 336:1988;385-388.
17. Ghelardini C., Galeotti N., Casamenti F., Malmberg-Aiello P., Pepeu G., Gualtieri F., Bartolini A. Central cholinergic antinociception induced by 5HT4 agonists: BIMU 1 and BIMU 8. Life Sci. 58(25):1996;2297-2309.
18. Herrero J.F., Parrado A., Cervero F. Central and peripheral actions of the NSAID ketoprofen on spinal cord nociceptive reflexes. Neuropharmacology. 36:1997;1425-1431.
19. Hoyer D., Clarke D.E., Fozard J.R., Hartig P.R., Martin G.R., Mylecharane E.J., Saxena P.R., Humphrey P. VII. International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol. Rev. 46:1994;157-203.
20. Hunskaar S., Fasmer O.B., Hole K. Acetylsalicylic acid, paracetamol and morphine inhibit behavioural responses to intrathecally administered substance P or capsaicin. Life Sci. 37:1985;1835-1841.
21. Inoue T., Mashimo T., Shibata M., Shibuta S., Yoshiya I. Rapid development of nitric oxide-induced hyperalgesia depends on an alternate to the cGMP-mediated pathway in the rat neuropathic pain model. Brain Res. 792:1998;263-270.
22. Kubota T., Komatsu H., Kawamoto H., Yamada T. Studies on the effects of anti-inflammatory action of benzoyl-hydrotropic acid (ketoprofen) and others drugs with special reference to prostaglandin synthesis. Arch. Int. Pharmacodyn. 237:1979;169-176.
23. Le Bars D. Serotonin and pain. Osborne N.N., Hamon M. Neuronal Serotonin. 1988;171-229 Wiley, Chichester.
24. López-Muñoz F.J., Ventura R., Díaz I., Fernández-Guasti A., Tost D., Cabré F., Mauleón D. Antinociceptive effects of S(+)-ketoprofen and other analgesic drugs in a rat model of pain induced by uric acid. J. Clin. Pharmacol. 38:1988;11S-21S.
25. López-Muñoz F.J., Salazar L.A., Castañeda- Hernández G., Villarreal J.E. A new model to assess analgesic activity: pain-induced functional impairment in the rat (PIFIR model). Drug Dev. Res. 28:1993;169-175.
26. McCormack K. The spinal actions of nonsteroidal anti-inflammatory drugs and the dissociation between their anti-inflammatory and analgesic effects. Drugs. 47:1994;28-45.
27. Meller S.T., Dykstra C., Gebhart G.F. Production of endogenous nitric oxide and activation of soluble guanylate cyclase are required for N-methyl-D-aspartate-produced facilitation of the nociceptive tail-click reflex. Eur. J. Pharmacol. 214:1992;93-96.
28. Netter P., Lapicque F., Bannwarth B., Tamisier J.N., Thomas P., Royer R.J. Diffusion of intramuscular ketoprofen into the cerebrospinal fluid. Eur. J. Pharmacol. 29:1985;319-321.
29. O'Brien W.M., Grunwaldt E. Ketoprofen in the treatment of rheumatoid arthritis: double blind, crossover placebo comparison. Scand. J. Rheumatol. 5(Suppl. 14):1976;105-110.
30. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1982;Academic Press, New York.
31. Pelissier T., Alloui A., Caussade F., Dubray C., Cloarec A., Lavarenne J., Eschalier A. Paracetamol exerts a spinal antinociceptive effect involving an indirect interaction with 5-hydroxytryptamine3 receptors: in vivo and in vitro evidence. J. Pharmacol. Exp. Ther. 278(1):1996;8-14.
32. Pini L.A., Sandrini M., Vitale G. The antinociceptive action of paracetamol is associated with changes in the serotonergic system in the rat brain. Eur. J. Pharmacol. 308:1996;31-40.
33. Pini L.A., Vitale G., Sandrini M. Serotonin and opiate involvement in the antinociceptive effect of acetylsalicylic acid. Pharmacology. 54:1997;84-91.
34. Pini L.A., Vitale G., Ottani A., Sandrini M. Naloxone-reversible antinociception by paracetamol in the rat. J. Pharmacol. Exp. Ther. 280:1997;934-940.
35. Sacerdote P., Monza G., Mantegazza P. Diclofenac and pirprofen modify pituitary and hypothalamic beta-endorphin concentrations. Pharmacol. Res. Commun. 17:1985;679-684.
36. Sandrini M., Vitale G., Pini L.A. Central antinociceptive activity of acetylsalicylic acid is modulated by brain serotonin receptor subtypes. Pharmacology. 65(4):2002;193-197.
37. Sandrini M., Vitale G., Pini L.A. Effect of rofecoxib on nociception and the serotonin system in the rat brain. Inflamm. Res. 51(3):2002;154-159.
38. Srikiatkhachorn A., Tarasub N., Govitrapong P. Acetaminophen-induced antinociception via central 5-HT(2A) receptors. Neurochem. Int. 34(6):1999;491-498.
39. Suesa N., Fernández M.F., Gutiérrez M., Rufat M.J., Rotllán E., Calvo L., Mauleón D., Carganico G. Stereoselective cyclooxygenase inhibition in cellular models by the enantiomers of ketoprofen. Chirality. 5:1993;589-595.
40. 7 receptor: a target for novel therapeutic avenues? Investig. Drug. 1:1998;302-310.
41. 7 receptors in guinea-pig brain. Br. J. Pharmacol. 115:1995;107-116.
42. Yaksh T.L. Direct evidence that spinal serotonin and noradrenaline terminals mediate the spinal antinociceptive effects of morphine in the periaqueductal gray. Brain Res. 160:1979;180-185.
43. Yaksh T.L. Pharmacology and mechanisms of opioid analgesic activity. Acta Anaesthesiol. Scand. 41:1997;94-111.
44. Yaksh T.L., Rudy T.A. Chronic catheterization of the spinal subarachnoid space. Physiol. Behav. 17:1976;1031-1036.
45. Yaksh T.L., Wilson P.R. Spinal serotonin terminal system mediates antinociception. J. Pharmacol. Exp. Ther. 208:1979;446-453.
46. Zimmermann M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain. 16:1983;109-110.